Human anionic trypsinogen: properties of autocatalytic activation and degradation and implications in pancreatic diseases.
Human pancreatic secretions contain two major trypsinogen isoforms, cationic and anionic trypsinogen, normally at a ratio of 2 : 1. Pancreatitis, pancreatic cancer and chronic alcoholism lead to a characteristic reversal of the isoform ratio, and anionic trypsinogen becomes the predominant zymogen secreted. To understand the biochemical consequences of these alterations, we recombinantly expressed and purified both human trypsinogens and documented characteristics of autoactivation, autocatalytic degradation and Ca2+-dependence. Even though the two trypsinogens are approximately 90% identical in their primary structure, we found that human anionic trypsinogen and trypsin exhibited a significantly increased (10-20-fold) propensity for autocatalytic degradation, relative to cationic trypsinogen and trypsin. Furthermore, in contrast to the characteristic stimulation of the cationic proenzyme, acidic pH inhibited autoactivation of anionic trypsinogen. In mixtures of cationic and anionic trypsinogen, an increase in the proportion of the anionic proenzyme had no significant effect on the levels of trypsin generated by autoactivation or by enterokinase at pH 8.0 in 1 mm Ca2+- conditions that were characteristic of the pancreatic juice. In contrast, rates of trypsinogen activation were markedly reduced with increasing ratios of anionic trypsinogen under conditions that were typical of potential sites of pathological intra-acinar trypsinogen activation. Thus, at low Ca2+ concentrations at pH 8.0, selective degradation of anionic trypsinogen and trypsin caused diminished trypsin production; while at pH 5.0, inhibition of anionic trypsinogen activation resulted in lower trypsin yields. Taken together, the observations indicate that up-regulation of anionic trypsinogen in pancreatic diseases does not affect physiological trypsinogen activation, but significantly limits trypsin generation under potential pathological conditions.
Kukor
Zoltán
Z
Department of Molecular and Cell Biology, Goldman School of Dental Medicine, Boston University, USA.
Tóth
Miklós
M
Sahin-Tóth
Miklós
M
D000818:Animals; D002118:Calcium / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009154:Mutation; D010182:Pancreatic Diseases / Q000201:enzymology*; D020033:Protein Isoforms / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D014357:Trypsin; D014362:Trypsinogen / Q000235:genetics / Q000378:metabolism*
D020033:Protein Isoforms; D011994:Recombinant Proteins; C064831:PRSS2 protein, human; D014362:Trypsinogen; D014357:Trypsin; D002118:Calcium